Clinical Scorecard: Impact of Perioperative Blood Transfusion on Overall and Disease-Free Survival Following Radical Gastrectomy in Stage II/III Gastric Cancer: A Propensity Score Matched Study

At a Glance

Key Highlights

• Perioperative blood transfusion is often required due to anemia and intraoperative blood loss during radical gastrectomy for advanced gastric cancer.
• There is controversy whether BTF independently worsens overall survival (OS) and disease-free survival (DFS) or is a confounding factor related to tumor stage and surgical complexity.
• This retrospective study used propensity score matching to minimize bias and assess the association between BTF and oncological outcomes.

Guideline-Based Recommendations

Diagnosis

• Use pathological diagnosis and staging according to the Seventh UICC TNM system for gastric cancer.
• Assess anemia and hemoglobin levels preoperatively to guide transfusion needs.

Management

• Perform radical gastrectomy with D2 or D2+ lymphadenectomy following Japanese gastric cancer treatment guidelines.
• Administer perioperative blood transfusion when hemoglobin <80 g/L or between 80-100 g/L with risk factors (age >65, cardiovascular/respiratory disease, hemodynamic instability).
• Apply prophylactic antibiotics postoperatively for 3-5 days.
• Use adjuvant chemotherapy with fluorouracil and platinum-based regimens within 6 months post-surgery.

Monitoring & Follow-up

• Follow-up at 1 month post-surgery, then every 3 months for 2 years, every 6 months up to 5 years, then annually.
• Monitor physical exam, serum tumor markers, imaging (CT/ultrasound every 6 months, endoscopy every 2 years), and additional imaging if metastasis suspected.

Risks

• Potential negative impact of perioperative blood transfusion on long-term survival possibly mediated by immunomodulation and inflammation.
• Confounding factors such as advanced tumor stage, age, and surgical complexity may influence outcomes associated with BTF.

Patient & Prescribing Data

Patients undergoing radical gastrectomy for stage II/III gastric adenocarcinoma with perioperative anemia or blood loss

Blood transfusion decisions should consider hemoglobin thresholds and patient risk factors; minimizing transfusion may improve oncological outcomes but must balance perioperative safety.

Clinical Best Practices

• Careful preoperative assessment of anemia and optimization to reduce transfusion needs.
• Strict adherence to transfusion indications based on hemoglobin levels and clinical risk factors.
• Use of propensity score matching in research to control for confounding variables when assessing BTF impact.
• Comprehensive postoperative follow-up including imaging and tumor marker surveillance to detect recurrence early.

References

• Japanese gastric cancer treatment guidelines
• Seventh UICC TNM Staging System for Gastric Cancer